Genscript Biotech Management
Management criteria checks 1/4
Genscript Biotech's CEO is Weihui Shao, appointed in Jul 2021, has a tenure of 3.5 years. total yearly compensation is $2.48M, comprised of 14.3% salary and 85.7% bonuses, including company stock and options. directly owns 0.034% of the company’s shares, worth HK$6.91M. The average tenure of the management team and the board of directors is 3.8 years and 1.8 years respectively.
Key information
Weihui Shao
Chief executive officer
US$2.5m
Total compensation
| CEO salary percentage | 14.3% |
| CEO tenure | 3.5yrs |
| CEO ownership | 0.03% |
| Management average tenure | 3.8yrs |
| Board average tenure | 1.8yrs |
Recent management updates
Recent updates
Market Still Lacking Some Conviction On Genscript Biotech Corporation (HKG:1548)
Nov 19
Is Genscript Biotech (HKG:1548) Using Debt In A Risky Way?
Oct 01What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?
Sep 16After Leaping 44% Genscript Biotech Corporation (HKG:1548) Shares Are Not Flying Under The Radar
Aug 02Slammed 28% Genscript Biotech Corporation (HKG:1548) Screens Well Here But There Might Be A Catch
Jun 05A Look At The Fair Value Of Genscript Biotech Corporation (HKG:1548)
May 10Is Genscript Biotech (HKG:1548) A Risky Investment?
Apr 13Investors Appear Satisfied With Genscript Biotech Corporation's (HKG:1548) Prospects As Shares Rocket 29%
Mar 13Genscript Biotech Corporation (HKG:1548) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Jan 26Is Genscript Biotech (HKG:1548) A Risky Investment?
Nov 21Is Genscript Biotech (HKG:1548) A Risky Investment?
Aug 22Time To Worry? Analysts Just Downgraded Their Genscript Biotech Corporation (HKG:1548) Outlook
Apr 04Analysts Have Been Trimming Their Genscript Biotech Corporation (HKG:1548) Price Target After Its Latest Report
Apr 03Is Genscript Biotech (HKG:1548) A Risky Investment?
Apr 02Genscript Biotech Corporation (HKG:1548) Shares Could Be 25% Below Their Intrinsic Value Estimate
Feb 07What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?
Dec 14Genscript Biotech Corporation (HKG:1548) Shares Could Be 22% Below Their Intrinsic Value Estimate
Nov 09Is Genscript Biotech (HKG:1548) Using Debt Sensibly?
Oct 22Health Check: How Prudently Does Genscript Biotech (HKG:1548) Use Debt?
Apr 03Does Genscript Biotech (HKG:1548) Have A Healthy Balance Sheet?
Oct 03Is It Time To Consider Buying Genscript Biotech Corporation (HKG:1548)?
Sep 07Estimating The Fair Value Of Genscript Biotech Corporation (HKG:1548)
Aug 16Is It Time To Consider Buying Genscript Biotech Corporation (HKG:1548)?
Jun 03Is Genscript Biotech Corporation (HKG:1548) Trading At A 49% Discount?
May 13Is Genscript Biotech (HKG:1548) Using Debt In A Risky Way?
Apr 16Could The Genscript Biotech Corporation (HKG:1548) Ownership Structure Tell Us Something Useful?
Mar 20CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$177m |
| Mar 31 2024 | n/a | n/a | -US$136m |
| Dec 31 2023 | US$2m | US$353k | -US$95m |
Compensation vs Market: Weihui's total compensation ($USD2.48M) is above average for companies of similar size in the Hong Kong market ($USD501.12K).
Compensation vs Earnings: Insufficient data to compare Weihui's compensation with company performance.
CEO
Weihui Shao (44 yo)
3.5yrs
Tenure
US$2,477,000
Compensation
Ms. Weihui Shao is Chief Operating Officer of Genscript Biotech Corporation from July 08, 2021 and serves as its Rotating Chief Executive Officer since January 01, 2023. She joined the Genscript Biotech Co...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 9.4yrs | US$495.00k | 0.015% HK$ 3.1m | |
| CEO & COO | 3.5yrs | US$2.48m | 0.034% HK$ 6.9m | |
| Co-Founder | 23yrs | US$659.00k | 0.038% HK$ 7.8m | |
| Co-Founder & Non-Executive Director | no data | no data | 0.030% HK$ 6.1m | |
| Co-Founder & Executive Director | 2.1yrs | US$531.00k | no data | |
| Chief Strategy Officer & Executive Director | 4.2yrs | US$320.00k | 0.055% HK$ 11.3m | |
| Chief Financial Officer | 4.1yrs | no data | no data | |
| Chief Marketing Officer for GenScript Life Science Group | less than a year | no data | no data |
3.8yrs
Average Tenure
56yo
Average Age
Experienced Management: 1548's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 9.4yrs | US$495.00k | 0.015% HK$ 3.1m | |
| Co-Founder | 9.7yrs | US$659.00k | 0.038% HK$ 7.8m | |
| Co-Founder & Non-Executive Director | 9.7yrs | no data | 0.030% HK$ 6.1m | |
| Co-Founder & Executive Director | 2.7yrs | US$531.00k | no data | |
| Chief Strategy Officer & Executive Director | 4.2yrs | US$320.00k | 0.055% HK$ 11.3m | |
| Member of Advisory Board | less than a year | no data | no data | |
| Member of Advisory Board | 5.3yrs | no data | no data | |
| Independent Non-Executive Director | less than a year | no data | no data | |
| Member of Scientific Advisory Board | less than a year | no data | no data | |
| Independent Non-Executive Director | less than a year | no data | no data | |
| Independent Non-Executive Director | less than a year | no data | no data | |
| Independent Non-Executive Director | less than a year | no data | no data |
1.8yrs
Average Tenure
61.5yo
Average Age
Experienced Board: 1548's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/06 00:15 |
| End of Day Share Price | 2025/01/06 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Genscript Biotech Corporation is covered by 20 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Linda Lu | BOCI Research Ltd. |
| Jin Zhang | China International Capital Corporation Limited |
| Yue-Kwong Lui | China Renaissance Securities |